ENTITY
SK Biopharmaceuticals

SK Biopharmaceuticals (326030 KS)

128
Analysis
Health CareSouth Korea
SK Biopharmaceuticals Co., Ltd. researches and develops new drugs. The Company develops and markets brain disorders treatment drugs, central nervous system disorders treatment drugs, and other products. SK Biopharmaceuticals markets its products worldwide.
more
06 Sep 2024 17:23

Key Flow Trading Opportunities After KRX Suddenly Added POSCO Holdings to the BBIG Battery Mix

This post covers the September rebalancing results for the KRX BBIG Index and dives into the standout flow trading opportunities sparked by the...

Logo
517 Views
Share
31 Jul 2024 13:31

KRX’s September Major Rebalancing Events: Why We Should Focus on KRX BBIG

This post examines flow trading opportunities arising from the KRX BBIG's September rebalancing, focusing on the impact of four stocks in the top...

Logo
278 Views
Share
18 May 2024 01:29

SK Biopharmaceuticals (326030 KS): Resumption of US Sales Growth Raises Hope for Annual Profit

In 1Q24, SK Biopharmaceuticals posted Xcopri U.S. sales of KRW90.9B, up 69% YoY and 17% QoQ. The company remains confident to meet Xcopri annual...

Logo
411 Views
Share
13 Oct 2024 07:30

APAC Healthcare Weekly (Oct 13)- CSPC Pharma, Hugel, Astellas, Ono Pharma, and Hanmi Pharm

Nobel Peace prize comes in the backdrop of a series of conflicts in the Middle East, Ukraine, and Sudan. However, far away from the conflict zones,...

Logo
420 Views
Share
28 Aug 2024 07:05

KRX Short Interest Weekly (Aug 23rd): Hlb

We analyzed KRX short interest report for the past week. We estimate the short interests to be USD 5.2bn and highlighted short interest changes in...

Logo
167 Views
Share
x